- Home
- RCS vs CNTX Comparison
RCS vs CNTX Comparison
Compare RCS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | CNTX |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.8M | 283.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RCS | CNTX |
|---|---|---|
| Price | $5.48 | $2.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 158.3K | ★ 921.1K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.09 | $0.49 |
| 52 Week High | $8.00 | $3.62 |
Technical Indicators
Market Signals| Indicator | RCS | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 48.82 |
| Support Level | N/A | $2.07 |
| Resistance Level | $5.81 | $2.72 |
| Average True Range (ATR) | 0.16 | 0.29 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 60.18 | 16.67 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.